Expansion Ventures Creative Diagnostics has actively expanded its service portfolio in 2026 with Lipidomics services, ELISA Kit Development, Peritoneal Fibrosis Model services, RSV Animal Model services, Nipah virus antigen and antibody offerings, and an Integrated CRO Platform powered by AI. This indicates multiple growth avenues and cross-sell opportunities for contract research, assay development, and specialized model services to diagnostic manufacturers and biopharma clients.

Broadened Assay Capabilities The company emphasizes rapid development and manufacturing of point-of-care assays including lateral flow, flow-through, and ELISA tests with diverse labeling technologies (fluorescent, colloidal gold, paramagnetic) and high-sensitivity readouts. This creates sales potential for customers seeking end-to-end assay development, manufacturing scale-up, and high-quality controls and reagents.

Integrated CRO Platform Launch of an Integrated CRO Platform for AI-powered infectious disease drug discovery signals a push into data-driven research services. There is a cross-sell opportunity to provide computational biology support, AI-enabled screening, and contract analytics alongside wet-lab CRO capabilities.

Global Diagnostic Focus With offerings spanning antibodies, viral antigens, diagnostic reagents, and GMP biologics manufacturing for biopharma, Creative Diagnostics positions itself as a one-stop supplier for assay components and contract manufacturing, enabling sales to diagnostic manufacturers, biotech startups, and CROs seeking vetted reagents and scalable production.

Publicity Momentum A string of 2026 press releases announcing new services and product lines suggests heightened visibility and credibility in the market. This momentum can be leveraged in outbound outreach, partner programs, and co-marketing with distributors or larger lab networks to accelerate lead generation and channel partnerships.